SA, F., MD, K., RE, H., E, B., JS, H., H, K., . . . PL, W. (1992). Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: A report from the Childrens Cancer Study Group. Medical and pediatric oncology, 20(2), 124. https://doi.org/10.1002/mpo.2950200207
Chicago Style (17th ed.) CitationSA, Feig, et al. "Determination of the Maximum Tolerated Dose of Idarubicin When Used in a Combination Chemotherapy Program of Reinduction of Childhood ALL at First Marrow Relapse and a Preliminary Assessment of Toxicity Compared to That of Daunorubicin: A Report from the Childrens Cancer Study Group." Medical and Pediatric Oncology 20, no. 2 (1992): 124. https://doi.org/10.1002/mpo.2950200207.
MLA (9th ed.) CitationSA, Feig, et al. "Determination of the Maximum Tolerated Dose of Idarubicin When Used in a Combination Chemotherapy Program of Reinduction of Childhood ALL at First Marrow Relapse and a Preliminary Assessment of Toxicity Compared to That of Daunorubicin: A Report from the Childrens Cancer Study Group." Medical and Pediatric Oncology, vol. 20, no. 2, 1992, p. 124, https://doi.org/10.1002/mpo.2950200207.
